Contact
Please use this form to send email to PR contact of this press release:
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
TO:
Please use this form to send email to PR contact of this press release:
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
TO: